Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2020

Open Access 01-12-2020 | Study protocol

Efficacy of a short-term residential smoking cessation therapy versus standard outpatient group therapy (‘START-Study’): study protocol of a randomized controlled trial

Authors: Jonas Dickreuter, Claudia Schmoor, Jürgen Bengel, Andreas Jähne, Jens A. Leifert

Published in: Trials | Issue 1/2020

Login to get access

Abstract

Background

In Germany, evidence-based outpatient smoking cessation therapies are widely available. Long-term abstinence rates, however, are limited. Studies suggest that short-term residential therapy enables a higher level of environmental control, more intense contact and greater support among patients and from therapists, which could result in higher abstinence rates. The aim of the current START-study is to investigate the long-term efficacy of a short-term residential therapy exclusively for smoking cessation, conducted by a mobile team of expert therapists.

Methods

A randomized controlled trial (RCT) is conducted to examine the efficacy of residential behavior therapeutic smoking cessation therapy compared to standard outpatient behavior therapeutic smoking cessation group therapy. Adult smokers consuming 10 or more cigarettes per day, who are willing to stop smoking, are randomized in a ratio of 1:1 between therapy groups. The primary endpoint is sustained abstinence for 6-month and 12-month periods. Secondary endpoints include smoking status after therapy, 7-day point abstinence after the 6-month and 12-month follow-ups, level of physical dependence, cost-effectiveness, use of nicotine replacement products, health-related quality of life, self-efficacy expectation for tobacco abstinence, motivational and volitional determinants of behavior change, self-reported depressive symptom severity, adverse events and possible side effects. Assessments will take place at baseline, post-therapy, and at 6-month and 12-month intervals after smoking cessation.

Discussion

There is a high demand for long-term effective smoking cessation therapies. This study represents the first prospective RCT to examine the long-term efficacy of a residential smoking cessation therapy program compared to standard outpatient group therapy as an active control condition. The residential therapeutic concept may serve as a new model to substantially enhance future cessation therapies and improve the understanding of therapeutic impact factors on tobacco abstinence. Utilizing a mobile team, the model could be applied efficiently to medical centers that do not have permanent and trained personnel for smoking cessation at their disposal.

Trial registration

German Register for Clinical Trials (Deutsches Register für Klinische Studien), DRKS00013466. Retrospectively registered on 1 April 2019. https://​www.​drks.​de/​drks_​web/​navigate.​do?​navigationId=​start.
Literature
1.
Stanaway JD, Afshin A, Gakidou E, Lim SS. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1923–94.
2.
Mons U, Gredner T, Behrens G, Stock C, Brenner H. Cancers due to smoking and high alcohol consumption. Dtsch Aerzteblatt Int. 2018;115:571–7.
3.
Kamal R, Srivastava AK, Kesavachandran CN. Meta-analysis approach to study the prevalence of chronic obstructive pulmonary disease among current, former and non-smokers. Toxicol Rep. 2015;2:1064–74.PubMedPubMedCentral
4.
GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1659–724.
5.
Hackshaw A, Morris JK, Boniface S, Tang J-L, Milenković D. Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. BMJ. 2018;360:j5855.PubMedPubMedCentral
6.
Goodchild M, Nargis N, Tursan d’Espaignet E. Global economic cost of smoking-attributable diseases. Tob Control. 2018;27:58–64.PubMed
7.
Deutsches Krebsforschungszentrum (ed.). Durch Rauchen und Passivrauchen verursachte Krebserkrankungen. Heidelberg: Deutsches Krebsforschungszentrum; 2008.
8.
Peto R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case–control studies. BMJ. 2000;321:323–9.PubMedPubMedCentral
9.
Hatzilia D, Malliarou M, Korompeli A, Tsoumakas K, Fildissis G. Smoking cessation process and quality of life. J Nurs Educ Pract. 2017;7:1–12.
10.
Babb S, Malarcher A, Schauer G, Asman K, Jamal A. Quitting smoking among adults — United States, 2000–2015. MMWR Morb Mortal Wkly Rep. 2017;65:1457–64.PubMed
11.
Breitling LP, Rothenbacher D, Stegmaier C, Raum E, Brenner H. Aufhörversuche und -wille bei älteren rauchern: Epidemiologische Beiträge zur Diskussion um “Lifestyle” versus “Sucht”. Dtsch Ärztebl Int. 2009;106:451–5.PubMedPubMedCentral
12.
Hughes JR, Helzer JE, Lindberg SA. Prevalence of DSM/ICD-defined nicotine dependence. Drug Alcohol Depend. 2006;85:91–102.PubMed
13.
Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction. 2004;99:29–38.PubMed
14.
Kröger C, Gomes de Matos E, Piontek D, Wenig JR. Ausstiegsversuche und Hilfsmittelnutzung unter Rauchern in Deutschland: Ergebnisse aus dem Epidemiologischen Suchtsurvey 2012. Gesundheitswesen. 2015;78:752–8.PubMed
15.
Raupach T, West R, Brown J. The most “successful” method for failing to quit smoking is unassisted cessation. Nicotine Tob Res. 2012;15:748–9.PubMed
16.
Batra A, Petersen KU, Hoch E, Andreas S, Bartsch G, Gohlke H, et al. S3 guideline “screening, diagnostics, and treatment of harmful and addictive tobacco use”: short version. Sucht. 2016;62:139–52.
17.
18.
Hartmann-Boyce J, Stead LF, Cahill K, Lancaster T. Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews. Addiction. 2014;109:1414–25.PubMed
19.
20.
Williams JM, Steinberg ML, Kenefake AN, Burke MV. An argument for change in tobacco treatment options guided by the ASAM criteria for patient placement. J Addict Med. 2016;10:291–9.PubMedPubMedCentral
21.
Hays JT, Croghan IT, Schroeder DR, Burke MV, Ebbert JO, McFadden DD, et al. Residential treatment compared with outpatient treatment for tobacco use and dependence. Mayo Clin Proc. 2011;86:203–9.PubMedPubMedCentral
22.
23.
Ferguson SG, Shiffman S. The relevance and treatment of cue-induced cravings in tobacco dependence. J Subst Abus Treat. 2009;36:235–43.
24.
Zelle SL, Gates KM, Fiez JA, Sayette MA, Wilson SJ. The first day is always the hardest: functional connectivity during cue exposure and the ability to resist smoking in the initial hours of a quit attempt. NeuroImage. 2017;151:24–32.PubMed
25.
2008 PHS Guideline Update Panel, Liaisons, and Staff. Treating tobacco use and dependence: 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary. Respir Care. 2008;53:1217–22.
26.
Jiménez Ruiz CA, de Granda Orive JI, Solano Reina S, Riesco Miranda JA, de Higes ME, Pascual Lledó JF, et al. Guidelines for the treatment of smoking in hospitalized patients. Arch Bronconeumol Engl Ed. 2017;53:387–94.
27.
Ussher M, Cropley M, Playle S, Mohidin R, West R. Effect of isometric exercise and body scanning on cigarette cravings and withdrawal symptoms. Addict Abingdon Engl. 2009;104:1251–7.
28.
Kotlyar M, Drone D, Thuras P, Hatsukami DK, Brauer L, Adson DE, et al. Effect of stress and bupropion on craving, withdrawal symptoms, and mood in smokers. Nicotine Tob Res. 2011;13:492–7.PubMedPubMedCentral
29.
30.
Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry SL, et al. Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline. Rockville: U.S. Department of Health and Human Services. Public Health Service; 2008.
31.
Kazemzadeh Z, Manzari ZS, Pouresmail Z. Nursing interventions for smoking cessation in hospitalized patients: a systematic review. Int Nurs Rev. 2017;64:263–75.PubMed
32.
33.
Barnett PG, Wong W, Jeffers A, Hall SM, Prochaska JJ. Cost-effectiveness of smoking cessation treatment initiated during psychiatric hospitalization: analysis from a randomized controlled trial. J Clin Psychiatry. 2015;76:e1285–91.PubMedPubMedCentral
34.
France EK, Glasgow RE, Marcus AC. Smoking cessation interventions among hospitalized patients: what have we learned? Prev Med. 2001;32:376–88.PubMed
35.
36.
Batra A, Buchkremer G. Tabakentwöhnung. Ein Leitfaden für Therapeuten. 1. Aufl. Stuttgart: Kohlhammer; 2004.
37.
Kröger C, Gröll J. Das Rauchfrei Programm – Jahresbericht 2018 – Berichtszeitraum 01.01.2017–31.12.2017. München: IFT-Gesundheitsförderung; 2018.
38.
Hays JT, Wolter TD, Eberman KM, Croghan IT, Offord KP, Hurt RD. Residential (inpatient) treatment compared with outpatient treatment for nicotine dependence. Mayo Clin Proc. 2001;76:124–33.PubMed
39.
40.
Hodgkin JE, Sachs DPL, Swan GE, Jack LM, Titus BL, Waldron SJS, et al. Outcomes from a patient-centered residential treatment plan for tobacco dependence. Mayo Clin Proc. 2013;88:970–6.PubMed
41.
Hoffman EH, Blackburn C, Cullari S. Brief residential treatment for nicotine addiction: a five-year follow-up study. Psychol Rep. 2001;89:99–105.PubMed
42.
Schoberberger R, Böhm G, Schroeder Y. Heavy dependent nicotine smokers – newfound lifestyle appreciation after quitting successfully. Experiences from inpatient smoking cessation therapy. Public Health. 2015;129:539–44.PubMed
43.
Schoberberger R, Bayer P, Groman E, Kunze M. Stationäre Rauchertherapie – Projekt Josefhof. Erste Resultate des Modellprojekts. Sucht Z Für Wiss Prax. 2000;46:424–7.
44.
Leifert JA, Engler U, Pschicholz B, Schulz C, Jähne A. Stationäre Behandlung ausschließlich zur Raucherentwöhnung—Ergebnisse einer Pilotstudie. Suchtmedizin. 2018;20:299–304.
45.
Seitz H, Bühringer G. Empfehlungen des wissenschaftlichen Kuratoriums der DHS zu Grenzwerten für den Konsum alkoholischer Getränke. Hamm: Deutsche Hauptstelle für Suchtfragen; 2010.
46.
Miller WR, Rollnick S, Demmel R. Motivational interviewing. 3. Auflage des Standardwerks in Deutsch. Freiburg im Breisgau: Lambertus; 2015.
47.
Mottillo S, Filion KB, Bélisle P, Joseph L, Gervais A, O’Loughlin J, et al. Behavioural interventions for smoking cessation: a meta-analysis of randomized controlled trials. Eur Heart J. 2009;30:718–30.PubMed
48.
Schwarzer R, Luszczynska A. How to overcome health-compromising behaviors: the Health Action Process Approach. Eur Psychol. 2008;13:141–51.
49.
Hoffmeyer-Zlotnik JHP, Glemser A, Heckel C, von der Heyde C, Quitt H, Deutschland, editors. Demographische standards: eine gemeinsame Empfehlung des ADM Arbeitskreis Deutscher Markt- und Sozialforschungsinstitute e.V., der Arbeitsgemeinschaft Sozialwissenschaftlicher Institute e.V. (ASI) und des Statistischen Bundesamtes. 5., überarb. und erw. Aufl. Wiesbaden: Statistisches Bundesamt; 2010.
50.
Bleich S, Havemann-Reinecke U, Kornhuber J. FTNA. Fagerström-Test für Nikotinabhängigkeit. Göttingen: Beltz; 2002.
51.
Jäkle C, Keller S, Baum E, Basler H-D. Skalen zur Selbstwirksamkeit und Entscheidungsbalance im Prozeß der Verhaltensänderung von Rauchern. Diagnostica. 1999;45:138–46.
52.
Radtke T, Scholz U, Keller R, Hornung R. Smoking is ok as long as I eat healthily: compensatory health beliefs and their role for intentions and smoking within the Health Action Process Approach. Psychol Health. 2012;27:91–107.PubMed
53.
Scholz U, Nagy G, Göhner W, Luszczynska A, Kliegel M. Changes in self-regulatory cognitions as predictors of changes in smoking and nutrition behaviour. Psychol Health. 2009;24:545–61.PubMed
54.
Löwe B, Spitzer RL, Zipfel S, Herzog W. Gesundheitsfragebogen für Patienten (PHQ-D). Komplettversion und Kurzform. Testmappe mit Manual, Fragebögen, Schablonen. 2. Auflage. Karlsruhe: Pfizer; 2002.
55.
56.
West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction. 2005;100:299–303.PubMed
57.
58.
Mills EJ, Wu P, Lockhart I, Wilson K, Ebbert JO. Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals. Tob Induc Dis. 2010;8:8.PubMedPubMedCentral
59.
Hajek P, Phillips-Waller A, Przulj D, Pesola F, Myers Smith K, Bisal N, et al. A randomized trial of e-cigarettes versus nicotine-replacement therapy. N Engl J Med. 2019;380:629–37.PubMed
60.
Kirchner TR, Shiffman S, Wileyto EP. Relapse dynamics during smoking cessation: recurrent abstinence violation effects and lapse-relapse progression. J Abnorm Psychol. 2012;121:187–97.PubMed
61.
Scheuermann TS, Richter KP, Rigotti NA, Cummins SE, Harrington KF, Sherman SE, et al. Accuracy of self-reported smoking abstinence in clinical trials of hospital-initiated smoking interventions. Addiction. 2017;112:2227–36.PubMedPubMedCentral
62.
Avila-Tang E, Al-Delaimy WK, Ashley DL, Benowitz N, Bernert JT, Kim S, et al. Assessing secondhand smoke using biological markers. Tob Control. 2013;22:164–71.PubMed
63.
Raja M, Garg A, Yadav PK, Jha K, Handa S. Diagnostic methods for detection of cotinine level in tobacco users: a review. J Clin Diagn Res. 2016;10:ZE04–6.PubMedPubMedCentral
64.
Zielińska-Danch W, Wardas W, Sobczak A, Szołtysek-Bołdys I. Estimation of urinary cotinine cut-off points distinguishing non-smokers, passive and active smokers. Biomarkers. 2007;12:484–96.PubMed
65.
Schupp PE, Batra A, Buchkremer G. Rauchanamnese zur Prädiktion des Abstinenzerfolges bei Rauchern. Sucht. 1997;43:4–10.
66.
Layden JE, Ghinai I, Pray I, Kimball A, Layer M, Tenforde M, et al. Pulmonary illness related to e-cigarette use in Illinois and Wisconsin — final report. N Engl J Med. 2020;382:903–16.PubMed
67.
National Academies of Sciences, Engineering, and Medicine. Public health consequences of e-cigarettes. Washington, DC: The National Academies Press; 2018.
68.
Velicer WF, Di Clemente CC, Rossi JS, Prochaska JO. Relapse situations and self-efficacy: an integrative model. Addict Behav. 1990;15:271–83.PubMed
69.
Devlin NJ, Brooks R. EQ-5D and the EuroQol Group: past, present and future. Appl Health Econ Health Policy. 2017;15:127–37.PubMedPubMedCentral
70.
Chen P-C, Kuo RN-C, Lai C-K, Tsai S-T, Lee Y-C. The relationship between smoking status and health-related quality of life among smokers who participated in a 1-year smoking cessation programme in Taiwan: a cohort study using the EQ-5D. BMJ Open. 2015;5:e007249.PubMedPubMedCentral
71.
Maheswaran H, Petrou S, Rees K, Stranges S. Estimating EQ-5D utility values for major health behavioural risk factors in England. J Epidemiol Community Health. 2013;67:172–80.PubMed
72.
Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health. 2009;12:S5–9.PubMed
73.
Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96:5–21.PubMed
74.
75.
Schwarzer R, Rochau U, Saverno K, Jahn B, Bornschein B, Muehlberger N, et al. Systematic overview of cost-effectiveness thresholds in ten countries across four continents. J Comp Eff Res. 2015;4:485–504.PubMed
76.
Ames SC, Croghan IT, Clark MM, Patten CA, Stevens SR, Schroeder DR, et al. Change in perceived stress, partner support, decisional balance, and self-efficacy following residential nicotine dependence treatment. J Addict Dis. 2008;27:73–82.PubMed
77.
Borland R, Yong H-H, Balmford J, Cooper J, Cummings KM, O’Connor RJ, et al. Motivational factors predict quit attempts but not maintenance of smoking cessation: findings from the International Tobacco Control Four country project. Nicotine Tob Res. 2010;12:S4–11.PubMedPubMedCentral
78.
79.
Sniehotta FF, Schwarzer R, Scholz U, Schüz B. Action planning and coping planning for long-term lifestyle change: theory and assessment. Eur J Soc Psychol. 2005;35:565–76.
80.
Gräfe K, Zipfel S, Herzog W, Löwe B. Screening psychischer Störungen mit dem “Gesundheitsfragebogen für Patienten (PHQ-D)”. Diagnostica. 2004;50:171–81.
81.
Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–13.PubMedPubMedCentral
82.
Kroenke K, Spitzer RL. The PHQ-9: a new depression diagnostic and severity measure. Psychiatr Ann. 2002;32:509–15.
83.
Curry SJ, Marlatt GA, Gordon J, Baer JS. A comparison of alternative theoretical approaches to smoking cessation and relapse. Health Psychol. 1988;7:545–56.PubMed
84.
Rice VH, Fox DH, Lepczyk M, Sieggreen M, Mullin M, Jarosz P, et al. A comparison of nursing interventions for smoking cessation in adults with cardiovascular health problems. Heart Lung. 1994;23:473–86.PubMed
85.
Cottraux JA, Harf R, Biossel J-P, Schbath J, Bouvard M, Gillet J. Smoking cessation with behaviour therapy of acupuncture – a controlled study. Behav Res Ther. 1983;21:417–24.PubMed
86.
Lando HA, McGovern PG, Barrios FX, Etringer BD. Comparative evaluation of American Cancer Society and American Lung Association smoking cessation clinics. Am J Public Health. 1990;80:554–9.PubMedPubMedCentral
87.
Hollis JF. Nurse-assisted counseling for smokers in primary care. Ann Intern Med. 1993;118:521.PubMed
88.
Hall SM, Humfleet GL, Reus VI, Muñoz RF, Hartz DT, Maude-Griffin R. Psychological intervention and antidepressant treatment in smoking cessation. Arch Gen Psychiatry. 2002;59:930.PubMed
89.
Deutsche Forschungsgemeinschaft DFG (ed.). Sicherung guter wissenschaftlicher Praxis. Weinheim: Wiley-VCH; 2013.
90.
Babhadiashar N, Sotoudeh M, Azizi E, Bashiri J, Didevar R, Malekzadeh R, et al. Correlation between cigarette smoking and urine cotinine level in gastric cancer patients. Iran J Pharm Res IJPR. 2014;13:313–8.PubMed
91.
Kim S. Overview of cotinine cutoff values for smoking status classification. Int J Environ Res Public Health. 2016;13:1236.PubMedCentral
92.
Gruber D, Schuurmans MM. Biomarker für Rauchen – Welche Cut-off-Werte sind anwendbar? Praxis. 2018;107:758–62.PubMed
93.
Gorber SC, Schofield-Hurwitz S, Hardt J, Levasseur G, Tremblay M. The accuracy of self-reported smoking: a systematic review of the relationship between self-reported and cotinine-assessed smoking status. Nicotine Tob Res. 2009;11:12–24.
94.
Carpenter JR, Kenward MG. Multiple imputation and its application. 1st ed. Chichester: Wiley; 2013.
95.
World Medical Association. WMA Declaration of Helsinki – ethical principles for medical research involving human subjects. Helsinki: WMA General Assembly; 2018.
Metadata
Title
Efficacy of a short-term residential smoking cessation therapy versus standard outpatient group therapy (‘START-Study’): study protocol of a randomized controlled trial
Authors
Jonas Dickreuter
Claudia Schmoor
Jürgen Bengel
Andreas Jähne
Jens A. Leifert
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Trials / Issue 1/2020
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-020-04253-x

Other articles of this Issue 1/2020

Trials 1/2020 Go to the issue

Review

Outcome reporting in neonates experiencing withdrawal following opioid exposure in pregnancy: a systematic review

Study protocol

Cognitive behavioural therapy for insomnia in patients with rheumatoid arthritis: protocol for the randomised, single-blinded, parallel-group Sleep-RA trial

Study protocol

Impact of the Maternal and Child Health handbook in Angola for improving continuum of care and other maternal and child health indicators: study protocol for a cluster randomised controlled trial

Letter

Response to the letter on “Comments to ‘PRevention of INCisional hernia after liver transplantation (PRINC trial): study protocol for a randomized controlled trial’ by Janusz Strzelczyk”

Letter

Flow controlled ventilation in Acute Respiratory Distress Syndrome associated with COVID-19: A structured summary of a study protocol for a randomised controlled trial

Research

The effects of exercise training on hypothalamic-pituitary-adrenal axis reactivity and autonomic response to acute stress—a randomized controlled study